- Home
- EQ vs LFT Comparison
EQ vs LFT Comparison
Compare EQ & LFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- LFT
- Stock Information
- Founded
- EQ 2017
- LFT 2012
- Country
- EQ United States
- LFT United States
- Employees
- EQ N/A
- LFT N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- LFT Real Estate Investment Trusts
- Sector
- EQ Health Care
- LFT Real Estate
- Exchange
- EQ Nasdaq
- LFT Nasdaq
- Market Cap
- EQ 85.1M
- LFT 92.1M
- IPO Year
- EQ 2018
- LFT N/A
- Fundamental
- Price
- EQ $1.34
- LFT $1.77
- Analyst Decision
- EQ Hold
- LFT Hold
- Analyst Count
- EQ 2
- LFT 1
- Target Price
- EQ $1.00
- LFT N/A
- AVG Volume (30 Days)
- EQ 725.3K
- LFT 192.0K
- Earning Date
- EQ 11-12-2025
- LFT 11-11-2025
- Dividend Yield
- EQ N/A
- LFT 13.64%
- EPS Growth
- EQ N/A
- LFT N/A
- EPS
- EQ N/A
- LFT 0.18
- Revenue
- EQ $16,553,000.00
- LFT $25,803,999.00
- Revenue This Year
- EQ N/A
- LFT $124.75
- Revenue Next Year
- EQ N/A
- LFT N/A
- P/E Ratio
- EQ N/A
- LFT $9.78
- Revenue Growth
- EQ N/A
- LFT N/A
- 52 Week Low
- EQ $0.27
- LFT $1.76
- 52 Week High
- EQ $2.35
- LFT $2.84
- Technical
- Relative Strength Index (RSI)
- EQ 43.10
- LFT 20.72
- Support Level
- EQ $1.41
- LFT $1.84
- Resistance Level
- EQ $1.64
- LFT $2.04
- Average True Range (ATR)
- EQ 0.11
- LFT 0.05
- MACD
- EQ -0.02
- LFT -0.03
- Stochastic Oscillator
- EQ 9.11
- LFT 2.69
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
About LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.